Skip to content

NASDAQ · mid · thesis board

VKTX Viking Therapeutics

Dual GLP-1/GIP agonist (VK2735)

View race

Thesis

Editorial summary — not a primary filing

Oral/SQ incretin VK2735 and metabolic assets; partnership and Phase 3 design are key.

Next gate

2026-09-15Company-guidedPh3 readout

Phase 3 start / design

33 days · Company: Company guidance

Survive-to-Event

ok

Cash covers the next gate with ~33 months spare (curated estimate).

Unverified estimate — not from a live SEC parse

Cash runway (~1034d)100%
Days to gate (33d)3%
Show math

$850M cash ÷ $25M/mo burn ≈ 1034 days. Source: curated SEC quarter figures.

Cash $850M as of 2026-03-31 (SEC)

Pipeline spine

  1. Preclinical
  2. Ph1
  3. Ph2
  4. Ph3
  5. Filed
  6. Approved
Secondary assets (1)
  • VK2809 THR-β · Ph2 · nash-masld

Rivals in this race

Open race →
NVOPh3okLLYPh3okAMGNPh3ok

Risks

  • Phase 3 design risk
  • Partner economics
  • Oral bioavailability
  • Giant competitors

Source trail

  1. SECCash from latest reported quarter (curated)as of 2026-03-31
  2. ClinicalTrials.govNCT06068946as of 2026-07-01
  3. CompanyIR / press disclosuresas of 2026-07-01